There’s “substantial reason to believe” that Rep. Chris Collins (R-NY) broke federal law and congressional rules by sharing insider information to spur investment and by meeting with government researchers to advocate for Innate Immunotherapeutics (ASX:IIL) – an Australian biotech that he’s invested in.
The Republican lawmaker recruited a number of investors for the company, including Dr. Tom Price, whose involvement in the company stirred up some trouble when he was vetted for his former role as Health and Human Services secretary.
Get the full story at our sister site, Drug Delivery Business News.
The post Ethics watchdog: Rep. Collins broke rules by advocating for biotech appeared first on MassDevice.